Outlook Therapeutics' Compensation Committee has approved stock option grants and performance-based cash bonuses for its CEO and CFO. The awards recognize their efforts in advancing the Biologics License Application (BLA) for the company's lead product candidate, ONS-5010 (bevacizumab-vikg).
Key Details
- Cash Bonuses: CEO Robert C. Jahr is eligible for a $420,000 bonus and CFO Lawrence A. Kenyon is eligible for a $200,000 bonus. These bonuses are contingent upon FDA approval of ONS-5010 on or before July 31, 2026.
- Stock Option Grants: The company granted 100,000 stock options to the CEO and 210,078 to the CFO. The options have an exercise price of $1.4304 per share and will vest on July 21, 2027.
- Rationale: The awards were granted in recognition of the executives' contributions to the ONS-5010 BLA process and, in the case of the cash bonuses, for non-payment of their 2025 annual bonuses.